We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS, Pfizer Discontinue Trial, Citing Increased Bleeding
Bristol-Myers Squibb (BMS) and Pfizer have discontinued a late-stage clinical trial of the blood-thinner apixaban for acute coronary syndrome (ACS) due to increased bleeding.